Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Eating ultra-processed foods could raise precancerous polyp risk for women under 50, according to research - 2Step by step instructions to Remain Spurred While Chasing after a Web-based Degree
- 3A Manual for the Right SUV for Seniors
- 4Fundamental Venture The board Apparatuses for Remote Groups
- 5A definitive Manual for the Over-Ear Earphones
- The most effective method to Recognize an Excellent Lab Precious stone
- Artemis 2 astronauts head for the moon after make-or-break engine burn (video)
- New movies to watch this weekend: See 'The Running Man' in theaters, rent 'One Battle After Another,' stream 'Nobody 2' on Peacock
- Record-breaking 'space laser' erupts from merging galaxies 8 billion light-years away
- Our favorite Space.com stories of 2025
- 'A perfect storm': Airlines cut flights and increase airfares as jet fuel price spikes
- Artemis II shares new lunar images while more than halfway to the moon
- Allow Innovative Progressions To have a Tremendous Effect
- Exclusive-Drugmakers raise US prices on 350 medicines despite pressure from Trump
